Jim Kelly
Stock Analyst at Leerink Partners
(0.29)
# 4,494
Out of 4,993 analysts
32
Total ratings
33.3%
Success rate
-18.9%
Average return
Main Sectors:
Stocks Rated by Jim Kelly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LRMR Larimar Therapeutics | Reiterated: Buy | $13 | $3.79 | +243.01% | 1 | Sep 14, 2026 | |
| PTCT PTC Therapeutics | Initiated Coverage: Buy | $98 | $65.37 | +49.92% | 1 | Sep 14, 2026 | |
| RYTM Rhythm Pharmaceuticals | Initiated Coverage: Buy | $133 | $97.71 | +36.12% | 1 | Sep 14, 2026 | |
| DGX Quest Diagnostics | Initiated Coverage: Hold | $135 | $246.45 | n/a | 1 | Feb 26, 2024 | |
| DOCS Doximity | Initiated Coverage: Hold | $32 | $26.11 | n/a | 1 | Feb 26, 2024 | |
| GDRX GoodRx Holdings | Initiated Coverage: Buy | $8 | $3.38 | n/a | 1 | Feb 26, 2024 | |
| AHCO AdaptHealth | Reiterated: Buy | $30 → $35 | $5.71 | n/a | 3 | Nov 5, 2021 | |
| CI The Cigna Group | Reiterated: Hold | $224 | $275.28 | n/a | 3 | Nov 5, 2021 | |
| HUM Humana | Reiterated: Buy | $494 → $528 | $386.22 | n/a | 2 | Nov 4, 2021 | |
| AGL agilon health | Reiterated: Buy | $35 | $89.16 | n/a | 3 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $85 → $83 | $28.33 | n/a | 2 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $320 | $427.71 | n/a | 2 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $403 → $430 | $410.95 | n/a | 2 | Oct 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $480 | $376.90 | n/a | 2 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $80 | $261.99 | n/a | 1 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $140 | $176.69 | n/a | 1 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $12 | $13.63 | n/a | 1 | Sep 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $5.33 | n/a | 2 | Sep 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $5.24 | n/a | 1 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $14 | $0.000001 | n/a | 1 | Sep 9, 2021 |
Larimar Therapeutics
Sep 14, 2026
Reiterated: Buy
Price Target: $13
Current: $3.79
Upside: +243.01%
PTC Therapeutics
Sep 14, 2026
Initiated Coverage: Buy
Price Target: $98
Current: $65.37
Upside: +49.92%
Rhythm Pharmaceuticals
Sep 14, 2026
Initiated Coverage: Buy
Price Target: $133
Current: $97.71
Upside: +36.12%
Quest Diagnostics
Feb 26, 2024
Initiated Coverage: Hold
Price Target: $135
Current: $246.45
Upside: n/a
Doximity
Feb 26, 2024
Initiated Coverage: Hold
Price Target: $32
Current: $26.11
Upside: n/a
GoodRx Holdings
Feb 26, 2024
Initiated Coverage: Buy
Price Target: $8
Current: $3.38
Upside: n/a
AdaptHealth
Nov 5, 2021
Reiterated: Buy
Price Target: $30 → $35
Current: $5.71
Upside: n/a
The Cigna Group
Nov 5, 2021
Reiterated: Hold
Price Target: $224
Current: $275.28
Upside: n/a
Humana
Nov 4, 2021
Reiterated: Buy
Price Target: $494 → $528
Current: $386.22
Upside: n/a
agilon health
Nov 1, 2021
Reiterated: Buy
Price Target: $35
Current: $89.16
Upside: n/a
Oct 29, 2021
Reiterated: Buy
Price Target: $85 → $83
Current: $28.33
Upside: n/a
Oct 25, 2021
Reiterated: Buy
Price Target: $320
Current: $427.71
Upside: n/a
Oct 20, 2021
Reiterated: Hold
Price Target: $403 → $430
Current: $410.95
Upside: n/a
Oct 14, 2021
Reiterated: Buy
Price Target: $480
Current: $376.90
Upside: n/a
Sep 27, 2021
Initiated Coverage: Hold
Price Target: $80
Current: $261.99
Upside: n/a
Sep 27, 2021
Initiated Coverage: Hold
Price Target: $140
Current: $176.69
Upside: n/a
Sep 23, 2021
Initiated Coverage: Buy
Price Target: $12
Current: $13.63
Upside: n/a
Sep 19, 2021
Reiterated: Buy
Price Target: $60
Current: $5.33
Upside: n/a
Sep 9, 2021
Rated: Buy
Price Target: $29
Current: $5.24
Upside: n/a
Sep 9, 2021
Rated: Buy
Price Target: $14
Current: $0.000001
Upside: n/a